Molecular Partners AG (MOLN) stock soared 36.16% in the pre-market trading session at the price of $22.48 after announcing topline data from the clinical study evaluating Ensovibep. MOLN is a clinical-stage biotechnology firm producing DARPin therapeutics to address diseases with no current treatment. The company has partnered with other pharmaceutical firms to advance DARPin therapeutics in ophthalmology, infectious disease, and oncology.
MOLN Published Positive Data for Ensovibep
On 10th January 2022, Molecular Partners and Novartis informed that the EMPATHY clinical trial Part A had met the primary endpoint of viral load reduction within eight days. The trial compared a single antiviral therapeutic candidate with placebo doses of ensovibep for the treatment of COVID-19. Two secondary endpoints demonstrated clinically significant benefits over placebo. Novartis ensured that it will in-license ensovibep from MOLN and will seek accelerated access globally.
The EMPATHY clinical trial has conducted by Novartis with MOLN as a supporter. It is a randomized, placebo-controlled, double-blind study in ambulatory patients with COVID-19. The Part A of the trial has enrolled over 407 candidates to identify ensovibep with efficacy and optimal safety. The clinical trial recruited patients from all around South Africa, Hungary, India, the USA, and the Netherlands.
Chief executive officer of Molecular Partners, Patrick Amstutz, remarked that these promising results arrived at a time of greater need for therapies such as ensovibep. They are happy to provide a potential therapy option for patients with limited access to COVID-19 treatments.
Aptrick added that today’s achievement resulted from the relentless team efforts to provide an antiviral drug candidate with proven safety and efficacy in clinical trials. They look ahead to demonstrate their abilities and the potential in virology and oncology for patients with unmet medical needs.
Chief executive officer of Novartis, Vas Narasimhan, commented that they are pleased to report the positive therapeutic results of ensovibep in the EMPATHY trial. The therapeutic candidate becomes a unique treatment option to fight the rapidly growing pandemic. Novartis will continue cooperating with MOLN on this treatment for COVID-19, Vas added.